Results 121 to 130 of about 17,288,534 (269)

Bio-Medical Library Bulletin, No. 63 (1979-09)

open access: yes, 1979
Bio-Medical Library. (1979). Bio-Medical Library Bulletin, No. 63 (1979-09).
Bio-Medical Library
core  

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

Brewer’s spent grain particle size and substitution level influence physicochemical and sensory properties of enriched cookies

open access: yesDiscover Food
Brewer’s spent grain (BSG) is a rich nutrient by-product generated during beer production; however, its industrial application in food products remains limited.
Parichat Putthasang   +6 more
doaj   +1 more source

Bio-Medical Library Bulletin, No. 90 (1986-05)

open access: yes, 1986
Bio-Medical Library. (1986). Bio-Medical Library Bulletin, No. 90 (1986-05).
Bio-Medical Library
core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

Bio-Medical Library Bulletin, No. 29 (1973-01)

open access: yes, 1973
Bio-Medical Library. (1973). Bio-Medical Library Bulletin, No. 29 (1973-01).
Bio-Medical Library
core  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

Biomimetic and Compressible Wood Phase Change Gel With Hierarchically Aligned Lamellar Structure for Controlled Thermal Management

open access: yesCarbon Energy
The recovery and utilization of ubiquitous low‐grade heat are crucial for mitigating the fossil energy crisis. However, uncontrolled spontaneous heat dissipation limits its practical application.
Jiazuo Zhou   +13 more
doaj   +1 more source

Bio-Medical Library Bulletin, No. 81 (1983-12)

open access: yes, 1983
Bio-Medical Library. (1983). Bio-Medical Library Bulletin, No. 81 (1983-12).
Bio-Medical Library
core  

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

open access: yesMolecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy